Browsing Tag
Eisai Co. Ltd.
4 posts
Can early LEQEMBI treatment delay Alzheimer’s by 8 years? Eisai reveals long-term data at CTAD 2025
Find out how Eisai and Biogen's LEQEMBI may slow Alzheimer’s by over 8 years in early-stage patients, as new CTAD 2025 data reveals long-term benefits.
Etalanetug shows over 90% tau biomarker reduction in Eisai’s DIAD trial update at CTAD 2025
Eisai’s etalanetug shows up to 90% reduction in novel tau biomarker in Alzheimer’s patients. Find out how it could reshape the AD treatment landscape.
Market soared—but these stocks crashed: Why Tonix, Dai-ichi Life, and Atour sank on April 9
Despite a record market rebound, Tonix, Dai-ichi Life, and Atour shares dropped on April 9. Discover the sector risks and policy fears behind the declines.
Newron and EA Pharma secure landmark licensing deal to advance schizophrenia treatment
In a move set to transform treatment options for patients with schizophrenia, Newron Pharmaceuticals S.p.A. (“Newron”) has entered…